This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
93
Intravenous placebo monthly during treatment phase.
Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Intravenous 10mg/mL based on weight monthly during treatment phase.
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85
Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.
Time frame: Baseline, Day 85
Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 and <100 Milligram Per Deciliter (mg/dL)
Time frame: Day 29, 57, 85
Percentage of Participants Achieving at Least 30 Percent Decrease in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame: Day 29, 57, 85
Change From Baseline in Lipid Parameters at Day 29, 57 and 85
Lipid parameters included: high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-high-density lipoprotein-cholesterol (non-HDL-C), triglyceride (TG), apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1). Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.
Time frame: Baseline, Day 29, 57, 85
Percent Change From Baseline in Lipid Parameters at Day 29, 57 and 85
Lipid parameters included: high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-high-density lipoprotein-cholesterol (non-HDL-C), triglyceride (TG), apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1). Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.
Time frame: Baseline, Day 29, 57, 85
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 141 that were absent before treatment or that worsened relative to pretreatment state. Treatment related: a TEAE deemed related to the study drug by the investigator. TEAEs included SAEs (TESAEs) as well as non-serious AEs which occurred during the study. The participants with TEAEs, SAEs and treatment-related TEAEs were reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Intravenous 10mg/mL based on weight monthly during treatment phase.
Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Intravenous 10mg/mL based on weight monthly during treatment phase.
Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Intravenous 10mg/mL based on weight monthly during treatment phase.
Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Orange County Research Center
Tustin, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Innovative Research of West Florida, Inc.
Clearwater, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
In Vivo Clinical Research, Inc.
Doral, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Kendall South Medical Center
Miami, Florida, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
North Georgia Internal Medicine
Woodstock, Georgia, United States
Vince and Associates Clinical Research
Overland Park, Kansas, United States
...and 34 more locations
Time frame: Day 1 up to Day 141
Number of Treatment-Emergent Adverse Events (TEAEs) by Severity
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Investigator assessed TEAEs as mild (did not interfere with participant's usual function), moderate (interfered to some extent with participant's usual function) or severe (interfered significantly with participant's usual function). TEAEs are events between first dose of study drug and up to Day 141 that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Day 1 up to Day 141
Number of Participants With Clinically Relevant Laboratory Abnormalities
Hematology (hemoglobin\[hgb\],hematocrit,red blood cell\[RBC\]\<0.8\*lower limit of normal\[LLN\],mean cell\[MC\] volume,MC hgb,MC hg concentration \<0.9\*LLN, greater than\[\>\] 1.1\*upper limit of normal\[ULN\], platelet \<0.5\*LLN,\>1.75\*ULN, white blood cell\[WBC\]\<0.6\*LLN,\>1.5\*ULN,neutrophil,lymphocyte \<0.8\*LLN,\>1.2\*ULN,eosinophil,basophil,monocyte \>1.2\*ULN);chemistry(total, direct, indirect bilirubin\[BR\]\>1.5\*ULN,aspartate aminotransferase\[AT\],alanine AT,alkaline phosphatase,gamma-glutyl transferase\>3.0\*ULN,protein,lactate dehydrogenase \<0.8\*LLN,\>1.2\*ULN,creatinine,blood urea nitrogen\>1.3\*ULN,uric acid \>1.2\*ULN,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN, sodium\<0.95\*LLN,\>1.05\*ULN,glucose\[GL\]\<0.6\*LLN,\>1.5\*ULN,amylase,lipase \>1.5\*ULN,creatinine kinase\>2.0\*ULN);urinalysis(pH \<4.5,\>8,specific gravity\<1.003 , \>1.030, GL,ketone,protein,hgb,BR,nitrite,leukocyte greater than or equal to \[\>=\]1, RBC, WBC \>=20);coagulation(prothrombin\[PT\],PT international ratio,partial thromboplastin time\>1.1\*ULN).
Time frame: Day 1 up to Day 141
Number of Participants With Clinically Significant Changes in Vital Signs and Electrocardiogram (ECG) Parameters
Criteria for clinical significant vital signs: maximum increase or decrease from baseline in supine systolic blood pressure (BP) greater than or equal to (\>=) 30 millimeter of mercury (mmHg), maximum increase or decrease from baseline in supine diastolic BP of \>=20 mmHg. Criteria for clinically significant ECG parameters: maximum increase of \>=25 percent (%) for baseline value of \>200 millisecond (msec) and maximum increase of \>=50% for baseline value of less than or equal to (\<=) 200 msec for PR and QRS interval; maximum increase from baseline of \>30 to \<=60 msec and maximum increase from baseline of \>60 msec for QT interval corrected using the Fridericia's formula (QTCF).
Time frame: Day 1 up to Day 141
Number of Participants With Anti-drug Antibody (ADA)
Human serum ADA samples of participants who received PF-04950615 (RN316) were analyzed for the presence of anti-PF-04950615 (RN316) antibodies by using the semi quantitative enzyme-linked immunosorbent assay (ELISA). Results with titer value \>=4.32 nanogram per milliliter of anti-PF-04950615 antibodies were counted as positive. Number of participants with presence of anti-PF-04950615 antibodies were reported in this outcome measure.
Time frame: Day 1 up to Day 141